Bottom line
What is FDAFX's expense ratio?
FDAFX's expense ratio is 0.79%, or about $79 a year on every $10,000 invested. That is more expensive than 71% of target-date funds we track (median 0.59%). Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated May 26, 2026
FDAFX fee table
| Net expense ratio | 0.79% |
|---|---|
| Gross expense ratio | 0.79% |
| Management fee | 0.54% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0% |
| Max deferred sales charge | 0% |
Source: Fund prospectus fee table, filed May 26, 2026
What FDAFX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| FDAFX | $651 | $813 | $989 | $1,497 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 0.79% expense ratio costs roughly $44,600 in lost growth, versus about $33,900 for the median target-date fund (0.59%).